• 1
    Burkitt D. A sarcoma involving the jaws in African children. Br J Surg 1958; 46: 218223.
  • 2
    Perkins AS,Friedberg JW. Burkitt lymphoma in adults. Hematology Am Soc Hematol Educ. Program 2008; 341348.
  • 3
    Smeland S,Blystad AK,Kvaloy SO, et al. Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: A 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Ann Oncol 2004; 15: 10721078.
  • 4
    Hoelzer D,Ludwig WD,Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996; 87: 495508.
  • 5
    Magrath I,Adde M,Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14: 925934.
  • 6
    Mead GM,Sydes MR,Walewsky J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: Results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002; 13: 12641274.
  • 7
    Rizzieri DA,Johnson JL,Niedzwiecki D, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: Final results of Cancer and Leukemia Group B Study 9251. Cancer 2004; 100: 14381448.
  • 8
    Di Nicola M,Carlo-Stella C,Mariotti J, et al. High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults. Br J Haematol 2004; 126: 815820.
  • 9
    Thomas DA,Cortes J,O'Brien S, et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 1999; 17: 24612470.
  • 10
    Thomas DA,Faderl S,O'Brien S, et al. Chemoimmunotherapy with Hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006; 106: 15691580.
  • 11
    Murphy SB,Bowman WP,Abromowitch M, et al. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (S Ig+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol 1986; 4: 17321739.
  • 12
    Todeschini G,Tecchio C,Degani D, et al. Eighty-one percent event-free survival in advanced Burkitt's lymphoma/leukemia: No differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol. Ann Oncol 1997; 8: S77S81.
  • 13
    Cheson BD,Horning SJ,Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 12441253.
  • 14
    Kujawski LA,Longo WL,Williams EC, et al. A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas. Cancer Invest 2007; 25: 8793.
  • 15
    van Imhoff GW,van der Holt B,MacKenzie MA, et al. Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. Leukemia 2005; 19: 945952.
  • 16
    Mead GM,Barrans SL,Qian W, et al. A prospective clinicopathological study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 2008; 112: 22482260.
  • 17
    Friedberg JW,Ciminello L,Kelly J, et al. Outcome of patients > age 40 with Burkitt lymphoma (BL) treated with aggressive chemotherapeutic regimens: Results from the International Burkitt Lymphoma Collaborative Group. Blood (ASH Annual Meeting Abstracts) 2005; 106: Abs#928.